Artiva Biotherapeutics, Inc. (以下简称Artiva) 近日宣布，任命Thad Huston先生为公司首席财务官（CFO）。作为一项重要的高管入职激励措施，公司同时向Huston先生授予了相应的股权奖励。
Thad Huston在生物科技与制药行业拥有丰富的财务管理与资本运作经验，其加入将进一步加强Artiva在财务战略、资金管理及企业发展方面的领导力量。此次任命及股权授予符合公司吸引和保留顶尖人才的战略，旨在支持Artiva持续推进其细胞治疗产品管线的研发与商业化进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.